BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial for Europe. Winter was previously SVP and head of Europe at Portola Pharmaceuticals Inc. before its acquisition by Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)....
BioCentury | Mar 6, 2021
Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...
BioCentury | Mar 5, 2021
Product Development

March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more

The ACCESS consortium, a coalition of regulatory authorities from the U.K., Australia, Canada, Singapore and Switzerland, released guidance on Thursday outlining the data needed to approve variant-specific modifications to authorized COVID-19 vaccines. According to the guidance, immunogenicity...
BioCentury | Mar 5, 2021
Translation in Brief

A stem cell therapy for brain metastases in breast cancer; plus a nanoparticle gene editing delivery tech and more

A team led by Khalid Shah from Harvard Medical School engineered allogeneic stem cells with an anti-EGFR camelid antibody fused to a death receptor ligand. Published in Science Advances, the therapy induced apoptosis of cancer...
BioCentury | Mar 3, 2021
Finance

March 3 Venture Roundup: Bionaut debuts with $20M; plus Janux, Century, Caribou, Medilink, Oxular and more

Bionaut Labs launched Wednesday with a $20 million round led by Khosla Ventures. Upfront Ventures, Revolution, Bold Capital and Compound also participated. The Los Angeles-based company is developing microscale robots to locally deliver biologics, nucleic...
BioCentury | Mar 3, 2021
Product Development

NIH halts COVID-19 convalescent plasma trial, renewing calls for FDA to withdraw authorization

NIH announced Tuesday that it has halted a trial of COVID-19 convalescent plasma to treat emergency department patients who developed mild-to-moderate symptoms of COVID-19 because there was no evidence of efficacy. The move renewed calls...
BioCentury | Mar 2, 2021
Management Tracks

Orphazyme hires Amgen’s Bourdon as CEO; plus Tsang joins Ropes & Gray, and updates from Karolinska, Kadmon, Immunicum, InnoCare, Abivax

Amgen Inc. (NASDAQ:AMGN) oncology veteran Christophe Bourdon will become CEO of Orphazyme A/S (CSE:ORPHA; NASDAQ:ORPH) April 1, pending confirmation by the Danish orphan neurodegenerative disease company’s board. At Amgen, Bourdon led commercialization planning and execution for multiple drugs as...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

Launched in 2016, Immune-Onc is part of a growing class of immuno-oncology companies converting myeloid cells from immune-suppressing into tumor-suppressing agents. The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed Advisors...
Items per page:
1 - 10 of 20077
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial for Europe. Winter was previously SVP and head of Europe at Portola Pharmaceuticals Inc. before its acquisition by Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)....
BioCentury | Mar 6, 2021
Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...
BioCentury | Mar 5, 2021
Product Development

March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more

The ACCESS consortium, a coalition of regulatory authorities from the U.K., Australia, Canada, Singapore and Switzerland, released guidance on Thursday outlining the data needed to approve variant-specific modifications to authorized COVID-19 vaccines. According to the guidance, immunogenicity...
BioCentury | Mar 5, 2021
Translation in Brief

A stem cell therapy for brain metastases in breast cancer; plus a nanoparticle gene editing delivery tech and more

A team led by Khalid Shah from Harvard Medical School engineered allogeneic stem cells with an anti-EGFR camelid antibody fused to a death receptor ligand. Published in Science Advances, the therapy induced apoptosis of cancer...
BioCentury | Mar 3, 2021
Finance

March 3 Venture Roundup: Bionaut debuts with $20M; plus Janux, Century, Caribou, Medilink, Oxular and more

Bionaut Labs launched Wednesday with a $20 million round led by Khosla Ventures. Upfront Ventures, Revolution, Bold Capital and Compound also participated. The Los Angeles-based company is developing microscale robots to locally deliver biologics, nucleic...
BioCentury | Mar 3, 2021
Product Development

NIH halts COVID-19 convalescent plasma trial, renewing calls for FDA to withdraw authorization

NIH announced Tuesday that it has halted a trial of COVID-19 convalescent plasma to treat emergency department patients who developed mild-to-moderate symptoms of COVID-19 because there was no evidence of efficacy. The move renewed calls...
BioCentury | Mar 2, 2021
Management Tracks

Orphazyme hires Amgen’s Bourdon as CEO; plus Tsang joins Ropes & Gray, and updates from Karolinska, Kadmon, Immunicum, InnoCare, Abivax

Amgen Inc. (NASDAQ:AMGN) oncology veteran Christophe Bourdon will become CEO of Orphazyme A/S (CSE:ORPHA; NASDAQ:ORPH) April 1, pending confirmation by the Danish orphan neurodegenerative disease company’s board. At Amgen, Bourdon led commercialization planning and execution for multiple drugs as...
BioCentury | Feb 27, 2021
Product Development

How variant surveillance could drive a sequencing boom

The push to keep up with COVID-19 variants could be the inflection point that turns genomic sequencing from a sophisticated technique into a widely accessible tool, with companies in the driver...
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

University of California Berkeley and University of California San Francisco announced Thursday a research collaboration with Genentech Inc. and Roche (SIX:ROG; OTCQX:RHHBY) to develop therapies for CNS disorders. The universities will receive up to $53 million...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

Launched in 2016, Immune-Onc is part of a growing class of immuno-oncology companies converting myeloid cells from immune-suppressing into tumor-suppressing agents. The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed Advisors...
Items per page:
1 - 10 of 20077